pharma news today glp-1 obesity drugs today Market Size to Hit USD 132.79 Bn by 2035 WHO Issues First-Ever Guidelines For

Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: A systematic review and meta-analysis

29 Intriguingly, the intracellular consequences of tirzepatide binding at the GLP-1R seem to be peculiarly biased towards cyclic adenosine monophosphate generation, at the expense of -arrestin recruitment

Clinically, low albumin (e.g., in liver disease or nephrotic syndrome) can lead to edema due to decreased oncotic pressure

This meta-analysis explored one in particular, that has a serious impact: Coenzyme Q10 (CoQ10) It analyzed 12 clinical trials involving 362 patients with hypertension

In April 2025 Pfizer was forced to discontinue a clinical trial with one of its experimental GLP-1 medicines to treat obesity due to potential drug induced liver injury found in one of the participants

Without insurance, typical retail pricing for a 28day carton of Mounjaro (4 pens)